Product
V116
Aliases
Pneumococcal 21-valent Conjugate Vaccine, Polyvalent pneumococcal conjugate vaccine (pPCV)
11 clinical trials
4 indications
Indication
Pneumococcal InfectionIndication
pneumococcal diseaseIndication
PneumoniaIndication
PneumococcalClinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal DiseaseStatus: Completed, Estimated PCD: 2024-02-16
Clinical trial
A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of AgeStatus: Completed, Estimated PCD: 2023-05-25
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIVStatus: Completed, Estimated PCD: 2023-07-13
Clinical trial
A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.Status: Completed, Estimated PCD: 2021-04-06
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal DiseaseStatus: Recruiting, Estimated PCD: 2025-02-12
Clinical trial
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or OlderStatus: Completed, Estimated PCD: 2023-05-16
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve AdultsStatus: Completed, Estimated PCD: 2023-05-18
Clinical trial
A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults.Status: Completed, Estimated PCD: 2021-07-12
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or OlderStatus: Completed, Estimated PCD: 2023-06-21
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Japanese Adults 65 Years of Age or OlderStatus: Completed, Estimated PCD: 2023-05-24
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or OlderStatus: Active (not recruiting), Estimated PCD: 2023-10-30